SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma

This study is testing mirdametinib, a drug that blocks a specific cell-signaling pathway (MEK), in children, teenagers, and young adults with low-grade glioma — a type of slow-growing brain or spinal cord tumor that is hard to treat with standard therapies. **You may be eligible if:** - You are at least 2 and under 25 years old (Phase 1) or broader age range (Phase 2) - You have a confirmed or suspected low-grade glioma (including certain mixed brain tumors) - Adequate tumor tissue is available for testing - You (and your guardian) are willing and able to give informed consent **You may NOT be eligible if:** - You have known retinal eye problems that could worsen with treatment (such as conditions affecting the macula or retinal vein) - You have a digestive condition that would prevent proper absorption of the drug (such as gastric bypass surgery) - You have known significant liver disease or bile duct problems (except for a harmless condition called Gilbert's syndrome) Talk to your doctor to see if this trial is right for you.